SCHEMBL6765375

SCHEMBL6765375

OC[C@H]1O[C@@H](n2cnc3c(NCc4ccccn4)ncnc32)[C@H](O)[C@@H]1O

nearest known ligand 0.77

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 7/20 0.77
SLC29A1 Q99808 4/20 0.77
TP53 P04637 3/20 0.77
TDP1 Q9NUW8 1/20 0.77
PAX8 Q06710 3/20 0.73
ADORA2A P29274 4/20 0.72
ADORA1 P30542 4/20 0.72
TSHR P16473 1/20 0.72
NFKB1 P19838 1/20 0.72
STAT6 P42226 1/20 0.72
GMNN O75496 1/20 0.72
BLM P54132 1/20 0.72
PMP22 Q01453 1/20 0.72
SMN1; SMN2 Q16637 1/20 0.70
MITF O75030 1/20 0.70
LMNA P02545 1/20 0.70
ADORA2B P29275 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10379208 0.91 ADORA3 (0.78) ADORA3SLC29A1TP53TDP1PAX8
N6-Benzyladenosine SCHEMBL15614834 0.87 ADORA3 (1.00) ADORA3SLC29A1TP53TDP1ADORA2A
N6-Benzyladenosine SCHEMBL20419282 0.87 ADORA3 (1.00) ADORA3SLC29A1TP53TDP1ADORA2A
N6-Benzyladenosine SCHEMBL472637 0.87 ADORA3 (1.00) ADORA3SLC29A1TP53TDP1ADORA2A
N6-Benzyladenosine SCHEMBL472635 0.87 ADORA3 (1.00) ADORA3SLC29A1TP53TDP1ADORA2A
N6-Benzyladenosine SCHEMBL23982413 0.87 ADORA3 (1.00) ADORA3SLC29A1TP53TDP1ADORA2A
N6-Benzyladenosine SCHEMBL20419317 0.87 ADORA3 (1.00) ADORA3SLC29A1TP53TDP1ADORA2A
N6-Benzyladenosine SCHEMBL3283829 0.87 ADORA3 (1.00) ADORA3SLC29A1TP53TDP1ADORA2A
N6-Benzyladenosine SCHEMBL219439 0.87 ADORA3 (1.00) ADORA3SLC29A1TP53TDP1ADORA2A
N6-Benzyladenosine SCHEMBL13966412 0.87 ADORA3 (1.00) ADORA3SLC29A1TP53TDP1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110718-A1 Anti-HCV nucleoside derivatives DEVOS RENE (GB) 2004-06-10 US claimed
CN-1466591-A Nucleoside derivatives - 2004-01-07 CN claimed
US-20030008841-A1 Anti-HCV nucleoside derivatives F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) 2003-01-09 US claimed
JP-1029395-A None JP disclosed
US-20040110718-A1 Anti-HCV nucleoside derivatives DEVOS RENE (GB) 2004-06-10 US disclosed
CN-1466591-A Nucleoside derivatives - 2004-01-07 CN disclosed
WO-2002018404-A9 NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C HOFFMANN LA ROCHE (CH) 2003-10-02 WO disclosed
EP-1315736-A2 NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C F. HOFFMANN-LA ROCHE AG (CH) 2003-06-04 EP disclosed
US-20030008841-A1 Anti-HCV nucleoside derivatives F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) 2003-01-09 US disclosed
WO-2002018404-A2 NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C F. HOFFMANN-LA ROCHE AG (CH) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030008841-A1 Anti-HCV nucleoside derivatives PNP, HAVCR2, NUDT14 ADORA3 102/4885SLC29A1 18/4885TP53 3695/4885
US-20040110718-A1 Anti-HCV nucleoside derivatives PNP, HAVCR2, NUDT14 ADORA3 102/4885SLC29A1 18/4885TP53 3695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.